The present invention relates to an ophthalmic pharmaceutical composition, comprising 0.06 to 40 parts by weight of a solid matrix, 0.4 to 55 parts by weight of a liquid matrix and 1 part by weight of an active pharmaceutical ingredient； the solid matrix is selected from the group consisting of polylactic acid, polyglycolic acid, polylactic acid-co-glycolic acid copolymer, and polyethylene glycol with a number average molecular weight of 800 to 10,000； the liquid matrix is a first liquid matrix and/or a second liquid matrix； the first liquid matrix is selected from the group consisting of diethyl succinate, diethyl tartrate, dimethyl glutarate and glycerol triacetate； when the liquid matrix is the first and second liquid matrixes, the second liquid matrix is selected from the group consisting of glycerol, propylene glycol, and polyethylene glycol with a number average molecular weight 70-750； when the liquid matrix is the second liquid matrix, the second liquid matrix is glycerol and/or propylene glycol, or a combination thereof with polyethylene glycol having a number average molecular weight of 70 to 750.
